期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 12, 期 11, 页码 1407-1417出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14787210.2014.959496
关键词
eflornithine; fexinidazole; gambiense; human African trypanosomiasis; melarsoprol; nifurtimox; oxaborole; SCYX-7158; second stage; sleeping sickness
Treatment of second-stage gambiense human African trypanosomiasis relied on toxic arsenic-based derivatives for over 50 years. The availability and subsequent use of eflornithine, initially in monotherapy and more recently in combination with nifurtimox (NECT), has drastically improved the prognosis of treated patients. However, NECT logistic and nursing requirements remain obstacles to its deployment and use in peripheral health structures in rural sub-Saharan Africa. Two oral compounds, fexinidazole and SCYX-7158, are currently in clinical development. The main scope of this article is to discuss the potential impact of new oral therapies to improve diagnosis-treatment algorithms and patients' access to treatment, and to contribute to reach the objectives of the recently launched gambiense human African trypanosomiasis elimination program.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据